The DOI matches its Crossref record; 133 of the 138 references it cites were found in a registry or an index.
PD-1 and PD-1 ligands: from discovery to clinical application
Abstract
Programmed cell death-1 (PD-1, Pdcd1), an immunoreceptor belonging to the CD28/CTLA-4 family negatively regulates antigen receptor signaling by recruiting protein tyrosine phosphatase, SHP-2 upon interacting with either of two ligands, PD-L1 or PD-L2. Because of the wide range of ligand distribution in the body, its biological significance pervades almost every aspect of immune responses including autoimmunity, tumor immunity, infectious immunity, transplantation immunity, allergy and immunological privilege. In this review, we would like to summarize the history of PD-1 research since its discovery and recent findings that suggest promising future for the clinical application of PD-1 agonists and antagonists to various human diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PD-1 interacts with an SHP2 tyrosine phosphatase domain, leading to dephosphorylation of signaling molecules downstream of the TCR and inhibiting TCR-mediated activation of IL2 production and T-cell proliferation (13).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Nguyen, L. T., Radhakrishnan, S., Ćirić, B., Tamada, K., Shin, T., Pardoll, D. M., Chen, L., Rodriguez, M., & Pease, L. R. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20021466 · Cited by 105 · cited 1×
“However, one group reported that cross-linking of PD-L2 induces stimulatory signal in dendritic cells (DCs), resulting in the augmented antigen presentation ( 26 , 27).”
BackgroundRetractedRadhakrishnan, S., Nguyen, L. T., Ćirić, B., Ure, D., Zhou, B., Tamada, K., Dong, H., Tseng, S.-Y., Shin, T., Pardoll, D. M., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.4.1830 · Cited by 73
RetractedFreeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Self-citationTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Tolerance, Danger, and the Extended Family
Matzinger, P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.005015 · Cited by 4,820
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Self-citationNishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Self-citationPD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 1×
“CTLA-4 and CTLA-4‐Ig fusion protein (abatacept) have proved their efficacy in the treatment of cancer and RA, respectively (121‐124), manipulations of co-stimulatory signals can result in tragic consequences ( 125 ).”
BackgroundCTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931 · cited 1×
“Upon antigen stimulation, the tyrosine residue located within ITSM is phosphorylated and recruits the protein tyrosine phosphatase SHP-2, which dephosphorylates downstream effector molecules such as Syk and PI3K in B cells and ZAP70 and CD3f in T cells (18, 20 , 21).”
BackgroundAutoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Ravetch, J. V., & Bolland, S. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.275 · Cited by 1,657
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes
Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubat, T., Yagita, H., & Honjo, T. (1996) · International Immunology · doi:10.1093/intimm/8.5.765 · Cited by 1,589
Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction
Trautmann, L., Janbazian, L., Chomont, N., Said, E. A., Gimmig, S., Bessette, B., Boulassel, M.-R., Delwart, E., Sepulveda, H., Balderas, R. S., et al. (2006) · Nature Medicine · doi:10.1038/nm1482 · Cited by 1,565
Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378
Self-citationLoss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2007) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,344
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
Cully, M., You, H., Levine, A. J., & Mak, T. W. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1819 · Cited by 1,233
Tissue expression of PD-L1 mediates peripheral T cell tolerance
Keir, M. E., Liang, S. C., Guleria, I., Latchman, Y. E., Qipo, A., Albacker, L. A., Koulmanda, M., Freeman, G. J., Sayegh, M. H., & Sharpe, A. H. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051776 · Cited by 1,211
THE NOD MOUSE: A Model of Immune Dysregulation
Anderson, M. S., & Bluestone, J. A. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115643 · Cited by 1,113
The Genetic Basis for Cardiomyopathy
Seidman, J. G., & Seidman, C. (2001) · Cell · doi:10.1016/s0092-8674(01)00242-2 · Cited by 1,046 · cited 1×
“Mutations in the cTnI gene have been found in familial DCM and hypertrophic cardiomyopathy ( 38 , 39).”
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity
Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., Rietz, C., Flies, D. B., Lau, J. S., Zhu, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.1089.65.3 · Cited by 1,018 · cited 1×
“Iwai et al. and Hirano et al. have shown using PD-L1-over-expressing P815 mastocytoma cell line that PD-L1 on tumor cells suppresses the cytolytic activity of CD8 T cells (95, 96 ).”
MethodBrown, J. A., Dorfman, D. M., Ma, F.-R., Sullivan, E. L., Munoz, O., Wood, C. R., Greenfield, E. A., & Freeman, G. J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.3.1257 · Cited by 968
Expression of Programmed Death 1 Ligands by Murine T Cells and APC
Yamazaki, T., Akiba, H., Iwai, H., Matsuda, H., Aoki, M., Tanno, Y., Shin, T., Tsuchiya, H., Pardoll, D. M., Okumura, K., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.10.5538 · Cited by 951
REGULATION OF IMMUNE RESPONSES THROUGH INHIBITORY RECEPTORS
Long, E. O. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.875 · Cited by 939 · cited 1×
“The PD-1 cytoplasmic domain has two tyrosine residues, the membrane-proximal one constitutes an immunoreceptor tyrosine-based inhibitory motif (ITIM) and the other an immunoreceptor tyrosine-based switch motif (ITSM) ( 16 , 17).”
BackgroundPD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection
Petrovas, C., Casazza, J. P., Brenchley, J. M., Price, D. A., Gostick, E., Adams, W. C., Precopio, M. L., Schacker, T., Roederer, M., Douek, D. C., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061496 · Cited by 889
Nomi, T., Sho, M., Akahori, T., Hamada, K., Kubo, A., Kanehiro, H., Nakamura, S., Enomoto, K., Yagita, H., Azuma, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2746 · Cited by 889
BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1
Watanabe, N., Gavrieli, M., Sedy, J. R., Yang, J., Fallarino, F., Loftin, S. K., Hurchla, M. A., Zimmerman, N., Sim, J., Zang, X., et al. (2003) · Nature Immunology · doi:10.1038/ni944 · Cited by 883
B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells
Tseng, S.-Y., Otsuji, M., Gorski, K., Huang, X., Slansky, J. E., Pai, S. I., Shalabi, A., Shin, T., Pardoll, D. M., & Tsuchiya, H. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.7.839 · Cited by 872 · cited 2×
“A variety of normal tissues express PD-L1 and PD-L2 transcripts, with high levels of expression in placenta, heart, lung and liver, low expression levels in spleen, lymph nodes and thymus and the absence of expression in brain (7, 9, 11, 12 ).”
BackgroundThompson, R. H., Kuntz, S. M., Leibovich, B. C., Dong, H., Lohse, C. M., Webster, W. S., Sengupta, S., Frank, I., Parker, A. S., Zincke, H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4303 · Cited by 869 · cited 1×
“SCCHN PD-L1 ND IHC(f) (98) Lung PD-L1 No IHC(f) (104) Renal cell PD-L1 Yes IHC(f, p) (105, 106 ) Esophagus PD-L1, PD-L2 Yes (L1 and L2) RT‐PCR (107) Stomach PD-L1 Yes IHC(p) (108) Breast PD-L1 ND IHC(f) (109) Oral squamous cell PD-L1 ND IHC(f) (110) Urothelial cell PD-L1 Yes IHC(f) (111) Ovary PD-L1, PD-L2 Yes (L1), n…”
Okazaki, T., Maeda, A., Nishimura, H., Kurosaki, T., & Honjo, T. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231486598 · Cited by 848
The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice
Ansari, M. J. I., Salama, A. D., Chitnis, T., Smith, R. N., Yagita, H., Akiba, H., Yamazaki, T., Azuma, M., Iwai, H., Khoury, S. J., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022125 · Cited by 814 · cited 1×
“In agreement with these observations, antibody blockade of PD-1‐PD-L pathway in prediabetic NOD mice induces type I diabetes within 10 days ( 47 ).”
BackgroundOhigashi, Y., Sho, M., Yamada, Y., Tsurui, Y., Hamada, K., Ikeda, N., Mizuno, T., Yoriki, R., Kashizuka, H., Yane, K., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1469 · Cited by 796
Ahmed, R., Salmi, A., Butler, L. D., Chiller, J. M., & Oldstone, M. B. (1984) · The Journal of experimental medicine · doi:10.1084/jem.160.2.521 · Cited by 792
Sheppard, K.-A., Fitz, L. J., Lee, J. M., Benander, C., George, J. A., Wooters, J., Qiu, Y., Jussif, J. M., Carter, L. L., Wood, C. R., et al. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.07.083 · Cited by 791
Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406351101 · Cited by 776
Blank, C., Brown, I., Peterson, A. C., Spiotto, M., Iwai, Y., Honjo, T., & Gajewski, T. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3259 · Cited by 772
Prokunina, L., Castillejo-López, C., Öberg, F., Gunnarsson, I., Berg, L., Magnusson, V., Brookes, A. J., Tentler, D., Kristjansdóttir, H., Gröndal, G., et al. (2002) · Nature Genetics · doi:10.1038/ng1020 · Cited by 769
Spontaneous Autoimmune Disease in FcγRIIB-Deficient Mice Results from Strain-Specific Epistasis
Bolland, S., & Ravetch, J. V. (2000) · Immunity · doi:10.1016/s1074-7613(00)00027-3 · Cited by 752
Signal Sequence Trap: a Cloning Strategy for Secreted Proteins and Type I Membrane Proteins
Tashiro, K., Tada, H., Heilker, R., Shirozu, M., Nakano, T., & Honjo, T. (1993) · Science · doi:10.1126/science.8342023 · Cited by 713
Okazaki, T., Tanaka, Y., Nishio, R., Mitsuiye, T., Mizoguchi, A., Wang, J., Ishida, M., Hiai, H., Matsumori, A., Minato, N., et al. (2003) · Nature Medicine · doi:10.1038/nm955 · Cited by 689
Self-citationKonishi, J., Yamazaki, K., Azuma, M., Kinoshita, I., Dosaka-Akita, H., & Nishimura, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0428 · Cited by 678
PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2
Carter, L. L., Fouser, L. A., Jussif, J., Fitz, L., Deng, B., Wood, C. R., Collins, M., Honjo, T., Freeman, G. J., & Carreno, B. M. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200203)32:3<634::aid-immu634>3.0.co;2-9 · Cited by 673
Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses
Liang, S. C., Latchman, Y. E., Buhlmann, J. E., Tomczak, M. F., Horwitz, B. H., Freeman, G. J., & Sharpe, A. H. (2003) · European Journal of Immunology · doi:10.1002/eji.200324228 · Cited by 639
PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells
Loke, P., & Allison, J. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0931259100 · Cited by 634
Tokuhiro, S., Yamada, R., Chang, X., Suzuki, A., Kochi, Y., Sawada, T., Suzuki, M., Nagasaki, M., Ohtsuki, M., Ono, M., et al. (2003) · Nature Genetics · doi:10.1038/ng1267 · Cited by 626
Ghebeh, H., Mohammed, S., Al-Omair, A., Qattant, A., Lehe, C., Al-Qudaihi, G., Elkum, N., Alshabanah, M., Bin Amer, S., Tulbah, A., et al. (2006) · Neoplasia · doi:10.1593/neo.05733 · Cited by 612 · cited 1×
“SCCHN PD-L1 ND IHC(f) (98) Lung PD-L1 No IHC(f) (104) Renal cell PD-L1 Yes IHC(f, p) (105, 106) Esophagus PD-L1, PD-L2 Yes (L1 and L2) RT‐PCR (107) Stomach PD-L1 Yes IHC(p) (108) Breast PD-L1 ND IHC(f) ( 109 ) Oral squamous cell PD-L1 ND IHC(f) (110) Urothelial cell PD-L1 Yes IHC(f) (111) Ovary PD-L1, PD-L2 Yes (L1),…”
Ribas, A., Camacho, L. H., Lopez-Berestein, G., Pavlov, D., Bulanhagui, C. A., Millham, R., Comin-Anduix, B., Reuben, J. M., Seja, E., Parker, C. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.109 · Cited by 591
Urbani, S., Amadei, B., Tola, D., Massari, M., Schivazappa, S., Missale, G., & Ferrari, C. (2006) · Journal of Virology · doi:10.1128/jvi.01177-06 · Cited by 588 · cited 2×
“In addition to HIV infection, Urbani et al. and Radziewicz et al. reported that PD-1-expressing exhausted CD8 T cells are also found in hepatitis C virus-infected patients ( 73 , 74).”
BackgroundThompson, R. H., Dong, H., Lohse, C. M., Leibovich, B. C., Blute, M. L., Cheville, J. C., & Kwon, E. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2599 · Cited by 569
Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4
Probst, H. C., McCoy, K., Okazaki, T., Honjo, T., & van den Broek, M. (2005) · Nature Immunology · doi:10.1038/ni1165 · Cited by 554
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.
Strome, S. E., Dong, H., Tamura, H., Voss, S. G., Flies, D. B., Tamada, K., Salomão, D. R., Cheville, J. C., Hirano, F., Lin, W. Y., et al. (2003) · PubMed · Cited by 540
Iwai, Y. (2004) · International Immunology · doi:10.1093/intimm/dxh194 · Cited by 527 · cited 1×
“PD-1 blockade has also been shown to suppress tumor metastasis using melanoma and colon cancer cell lines ( 101 ).”
BackgroundNishimura, H. (1998) · International Immunology · doi:10.1093/intimm/10.10.1563 · Cited by 500
Wu, C., Zhu, Y., Jiang, J., Zhao, J., Zhang, X.-G., & Xu, N. (2006) · Acta Histochemica · doi:10.1016/j.acthis.2006.01.003 · Cited by 495
Maker, A. V., Phan, G. Q., Attia, P., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Haworth, L. R., Levy, C., et al. (2005) · Annals of Surgical Oncology · doi:10.1245/aso.2005.03.536 · Cited by 492
Radziewicz, H., Ibegbu, C. C., Fernandez, M. L., Workowski, K. A., Obideen, K., Wehbi, M., Hanson, H. L., Steinberg, J. P., Masopust, D., Wherry, E. J., et al. (2007) · Journal of Virology · doi:10.1128/jvi.02021-06 · Cited by 483
Nakanishi, J., Wada, Y., Matsumoto, K., Azuma, M., Kikuchi, K., & Ueda, S. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0266-z · Cited by 473
Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance
Willimsky, G., & Blankenstein, T. (2005) · Nature · doi:10.1038/nature03954 · Cited by 445
A critical role for the programmed death ligand 1 in fetomaternal tolerance
Guleria, I., Khosroshahi, A., Ansari, M. J., Habicht, A., Azuma, M., Yagita, H., Noelle, R. J., Coyle, A., Mellor, A. L., Khoury, S. J., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050019 · Cited by 439 · cited 1×
“Guleira et al. ( 90 ) provided concrete data that support this idea using a murine abortion model.”
MethodEstablishment of NOD-Pdcd1-/-mice as an efficient animal model of type I diabetes
Wang, J., Yoshida, T., Nakaki, F., Hiai, H., Okazaki, T., & Honjo, T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505497102 · Cited by 437
Structural and Functional Analysis of the Costimulatory Receptor Programmed Death-1
Zhang, X., Schwartz, J.-C. D., Guo, X., Bhatia, S., Cao, E., Chen, L., Zhang, Z.-Y., Edidin, M. A., Nathenson, S. G., & Almo, S. C. (2004) · Immunity · doi:10.1016/s1074-7613(04)00051-2 · Cited by 410 · cited 1×
“Actually, structural and biochemical analyses showed that PD- 1 is monomeric in solution as well as on cell surface ( 15 ).”
BackgroundPD-1 Inhibits Antiviral Immunity at the Effector Phase in the Liver
Iwai, Y., Terawaki, S., Ikegawa, M., Okazaki, T., & Honjo, T. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022235 · Cited by 392 · cited 2×
“The first evidence for the PD-1-dependent suppression of anti-viral immunity was made by Iwai et al. ( 117 ), in which Pdcd1/ mice were challenged with lacZ-expressing ade-”
BackgroundThompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., et al. (2005) · Journal of Urology · doi:10.1016/s0022-5347(18)34858-4 · Cited by 386
Wintterle, Schreiner, Mitsdoerffer, Schneider, Chen, Meyermann, Weller, M., & Wiendl (2003) · 中国神经肿瘤杂志 · Cited by 366
Tolerance, Danger and the Extended Family
Matzinger, P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.immunol.12.1.991 · Cited by 335
Helms, C., Cao, L., Krueger, J. G., Wijsman, E. M., Chamian, F., Gordon, D., Heffernan, M., Daw, J. A. W., Robarge, J., Ott, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1268 · Cited by 299
Felix, S. B., Staudt, A., Dörffel, W. V., Stangl, V., Merkel, K., Pohl, M., Döcke, W. D., Morgera, S., Neumayer, H. H., Wernecke, K. D., et al. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00568-4 · Cited by 284
Ishida, M., Iwai, Y., Tanaka, Y., Okazaki, T., Freeman, G. J., Minato, N., & Honjo, T. (2002) · Immunology Letters · doi:10.1016/s0165-2478(02)00142-6 · Cited by 280
Selenko-Gebauer, N., Majdic, O., Szekeres, A., Höfler, G., Guthann, E., Korthäuer, U., Zlabinger, G., Steinberger, P., Pickl, W. F., Stockinger, H., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.7.3637 · Cited by 263
Nishimura, H., Agata, Y., Kawasaki, A., Sato, M., Imamura, S., Minato, N., Yagita, H., Nakano, T., & Honjo, T. (1996) · International Immunology · doi:10.1093/intimm/8.5.773 · Cited by 261
Structure and Chromosomal Localization of the Human PD-1 Gene (PDCD1)
Shinohara, T., Taniwaki, M., Ishida, Y., Kawaichi, M., & Honjo, T. (1994) · Genomics · doi:10.1006/geno.1994.1562 · Cited by 253
The dual-function CD150 receptor subfamily: the viral attraction
Sidorenko, S. P., & Clark, E. A. (2003) · Nature Immunology · doi:10.1038/ni0103-19 · Cited by 252
A PD‐1 polymorphism is associated with disease progression in multiple sclerosis
Kroner, A., Mehling, M., Hemmer, B., Rieckmann, P., Toyka, K. V., Mäurer, M., & Wiendl, H. (2005) · Annals of Neurology · doi:10.1002/ana.20514 · Cited by 249
T‐cell tolerance or function is determined by combinatorial costimulatory signals
Nurieva, R., Thomas, S., Nguyen, T., Martin‐Orozco, N., Wang, Y., Kaja, M., Yu, X., & Dong, C. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601146 · Cited by 245
Programmed Death-1 Targeting Can Promote Allograft Survival
Özkaynak, E., Wang, L., Goodearl, A., McDonald, K., Qin, S., O’Keefe, T., Duong, T., Smith, T., Gutierrez-Ramos, J.-C., Rottman, J. B., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.11.6546 · Cited by 243
Wan, B., Nie, H., Liu, A., Feng, G., He, D., Xu, R., Zhang, Q., Dong, C., & Zhang, J. Z. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.12.8844 · Cited by 233
Nielsen, C., Hansen, D., Husby, S., Jacobsen, B. B., & Lillevang, S. T. (2003) · Tissue Antigens · doi:10.1046/j.1399-0039.2003.00136.x · Cited by 232
Fc Receptors and Their Role in Immune Regulation and Autoimmunity
Takai, T. (2005) · Journal of Clinical Immunology · doi:10.1007/s10875-005-0353-8 · Cited by 231
E3 ubiquitin ligases as T cell anergy factors
Mueller, D. L. (2004) · Nature Immunology · doi:10.1038/ni1106 · Cited by 224
Göser, S., Andrassy, M., Buss, S. J., Leuschner, F., Volz, C. H., Öttl;, R., Zittrich;, S., Blaudeck, N., Hardt, S. E., Pfitzer, G., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.635664 · Cited by 224 · cited 1×
“Recently, Goser et al. ( 37 ) reported that immunization with cTnI but not with cTnT induced severe myocarditis in BALB/c and A/J mice, confirming the pathogenic role of autoimmune response against cTnI.”
BackgroundB7-H1 costimulation preferentially enhances CD28-independent T-helper cell function
Tamura, H., Dong, H., Zhu, G., Sica, G. L., Flies, D. B., Tamada, K., & Chen, L. (2001) · Blood · doi:10.1182/blood.v97.6.1809 · Cited by 218
B7 Family Molecules Are Favorably Positioned at the Human Maternal-Fetal Interface1
Petroff, M. G., Chen, L., Phillips, T. A., Azzola, D., Sedlmayr, P., & Hunt, J. S. (2003) · Biology of Reproduction · doi:10.1095/biolreprod.102.010058 · Cited by 197
Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption
Felix, S. B., Staudt, A., Landsberger, M., Grosse, Y., Stangl, V., Spielhagen, T., Wallukat, G., Wernecke, K. D., Baumann, G., & Stangl, K. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01794-6 · Cited by 189
Oscillating CD8+ T Cell Effector Functions after Antigen Recognition in the Liver
Isogawa, M., Furuichi, Y., & Chisari, F. V. (2005) · Immunity · doi:10.1016/j.immuni.2005.05.005 · Cited by 186
Das, S., Suarez, G., Beswick, E. J., Sierra, J. C., Graham, D. Y., & Reyes, V. E. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.5.3000 · Cited by 184
Novel mutation in cardiac troponin I in recessive idiopathic dilated cardiomyopathy
Murphy, R. T., Mogensen, J., Shaw, A., Kubo, T., Hughes, S., & McKenna, W. J. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15468-8 · Cited by 176
Raimondi, G., Shufesky, W. J., Tokita, D., Morelli, A. E., & Thomson, A. W. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.5.2808 · Cited by 176
Lin, S., Yen, J., Tsai, J., Tsai, W., Ou, T., Liu, H., & Chen, C. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20040 · Cited by 175
Prokunina, L., Padyukov, L., Bennet, A., de Faire, U., Wiman, B., Prince, J., Alfredsson, L., Klareskog, L., & Alarcón‐Riquelme, M. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20280 · Cited by 173
In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses
Shin, T., Yoshimura, K., Shin, T., Crafton, E. B., Tsuchiya, H., Housseau, F., Koseki, H., Schulick, R. D., Chen, L., & Pardoll, D. M. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050072 · Cited by 168
B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression
Trabattoni, D. (2003) · Blood · doi:10.1182/blood-2002-10-3065 · Cited by 159 · cited 1×
“HIV PD-1 CD8 T cell (69‐71) HIV PD-L1 Monocyte, B cells ( 72 ) HCV PD-1 CD8 T cells (73, 74) HBV PD-L1 Monocytes (75) H. pylori PD-L1 Gastric epithelium (76)”
BackgroundA new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese
Kong, E. K., Prokunina‐Olsson, L., Wong, W. H. S., Lau, C., Chan, T. M., Alarcón-Riquelme, M. E., & Lau, Y. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20966 · Cited by 155
He, Y., Zhang, G., Wang, X., Zhang, H., Yuan, Y., Li, D., & Feng, Z. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.8.4919 · Cited by 138
Hirata, S., Senju, S., Matsuyoshi, H., Fukuma, D., Uemura, Y., & Nishimura, Y. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.4.1888 · Cited by 137
PD-1/PD-L pathway and autoimmunity
Okazaki, T., & Wang, J. (2005) · Autoimmunity · doi:10.1080/08916930500124072 · Cited by 135
濱西, 潤. (2009) · Kyoto University Research Information Repository (Kyoto University) · Cited by 131
Tao, R., Wang, L., Han, R., Wang, T., Ye, Q., Honjo, T., Murphy, T. L., MURPHY, K. M. M., & Hancock, W. W. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.5774 · Cited by 128
Ferreirós-Vidal, I., Gómez-Reino, J. J., Barros, F., Carracedo, Á., Carreira, P. E., Gonzáléz‐Escribano, F., Liz, M., Martin, J. J., Ordi‐Ros, J., Vicario, J. L., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20436 · Cited by 120
Genetic susceptibility to type 1 diabetes
Maier, L. M., & Wicker, L. S. (2005) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.09.013 · Cited by 116
Removal of autoantibodies in dilated cardiomyopathy by immunoadsorption
Wallukat, G., Reinke, P., Dörffel, Y., Luther, H. P., Bestvater, K., Felix, S. B., & Baumann, G. (1996) · International Journal of Cardiology · doi:10.1016/0167-5273(96)02598-3 · Cited by 111
Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma
Tsushima, F., Tanaka, K., Otsuki, N., Youngnak‐Piboonratanakit, P., Iwai, H., Omura, K., & Azuma, M. (2005) · Oral Oncology · doi:10.1016/j.oraloncology.2005.07.013 · Cited by 106
Bolstad, A. I., Eiken, H. G., Rosenlund, B., Alarcón-Riquelme, M. E., & Jonsson, R. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10734 · Cited by 103
Kirchberger, S., Majdic, O., Steinberger, P., Blüml, S., Grabmeier‐Pfistershammer, K., Zlabinger, G. J., Deszcz, L., Kuechler, E., Knapp, W., & Stöckl, J. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.2.1145 · Cited by 97
Generation and genetic modification of dendritic cells derived from mouse embryonic stem cells
Senju, S., Hirata, S., Matsuyoshi, H., Masuda, M., Uemura, Y., Araki, K., Yamamura, K., & Nishimura, Y. (2003) · Blood · doi:10.1182/blood-2002-07-2254 · Cited by 97 · cited 1×
“Hirata et al. elaborated a method to generate DC from embryonic stem (ES) cells, because genetic modification is more easily performed on ES cells than freshly isolated cells that are the most popular source of DCs ( 82 , 83).”
MethodCD4+ PD-1+ T cells accumulate as unique anergic cells in rheumatoid arthritis synovial fluid.
Hatachi, S., Iwai, Y., Kawano, S., Morinobu, S., Kobayashi, M., Koshiba, M., Saura, R., Kurosaka, M., Honjo, T., & Kumagai, S. (2003) · PubMed · Cited by 92
Lee, S., Lee, Y.-A., Woo, D. H., Song, R., Park, E., Ryu, M.-H., Kim, Y.-H., Kim, K. S., Hong, S.-J., Yoo, M. C., et al. (2006) · Arthritis Research & Therapy · doi:10.1186/ar2071 · Cited by 90
Expression of PD-1, PD-L1, and PD-L2 in the Liver in Autoimmune Liver Diseases
Mataki, N., Kikuchi, K., Kawai, T., Higashiyama, M., Okada, Y., Kurihara, C., Hokari, R., Kawaguchi, A., Nagao, S., Kondo, T., et al. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00948.x · Cited by 85
Kobayashi, M., Kawano, S., Hatachi, S., Kurimoto, C., Okazaki, T., Iwai, Y., Honjo, T., Tanaka, Y., Minato, N., Komori, T., et al. (2005) · PubMed · Cited by 77
Ni, R., Ihara, K., Miyako, K., Kuromaru, R., Inuo, M., Kohno, H., & Hara, T. (2007) · Human Genetics · doi:10.1007/s00439-006-0309-8 · Cited by 73
Ding, H., Wu, X., Wu, J., Yagita∥, H., He, Y., Zhang, J., Ren, J., & Gao, W. (2006) · Clinical Immunology · doi:10.1016/j.clim.2005.10.017 · Cited by 65
Dzik, S. (2000) · Transfusion Medicine Reviews · doi:10.1016/s0887-7963(00)80157-1 · Cited by 64
Programmed Death-1 Gene Polymorphisms in Patients With Systemic Lupus Erythematosus in Taiwan
Wang, S., Chen, Y., Ou, T., Wu, C., Tsai, W., Liu, H., & Yen, J. (2006) · Journal of Clinical Immunology · doi:10.1007/s10875-006-9048-9 · Cited by 55
PDCD1: a tissue-specific susceptibility locus for inherited inflammatory disorders
James, E. S., Harney, S. M. J., Wordsworth, B. P., Cookson, W., Davis, S. J., & Moffatt, M. F. (2005) · Genes and Immunity · doi:10.1038/sj.gene.6364223 · Cited by 48
Pathogenic roles of cardiac autoantibodies in dilated cardiomyopathy
Okazaki, T., & Honjo, T. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.05.001 · Cited by 47
Okazaki, T., Otaka, Y., Wang, J., Hiai, H., Takai, T., Ravetch, J. V., & Honjo, T. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051984 · Cited by 46
Structural and Functional Analysis of the Costimulatory Receptor Programmed Death-1
Zhang, X., Schwartz, J.-C. D., Guo, X., Bhatia, S., Cao, E., Lorenz, M. C., Cammer, M., Chen, L., Zhang, Z., Edidin, M. A., et al. (2004) · Immunity · doi:10.1016/s1074-7613(04)00114-1 · Cited by 46
Geng, L., Jiang, G., Fang, Y. H., Dong, S., Xie, H., Chen, Y., Shen, M., & Zheng, S. (2006) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2006.00746.x · Cited by 41
Rejuvenating exhausted T cells during chronic viral infection.
Okazaki, T., & Honjo, T. (2006) · Cell · doi:10.1016/j.cell.2006.01.022 · Cited by 40
Role of abatacept in the management of rheumatoid arthritis
Nogid, A., & Pham, D. Q. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.11.020 · Cited by 39
Drug Insight: abatacept for the treatment of rheumatoid arthritis
Ruderman, E., & Pope, R. M. (2006) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0345 · Cited by 34
Zhong, X., Bai, C., Gao, W., Strom, T. B., & Rothstein, T. L. (2004) · International Immunology · doi:10.1093/intimm/dxh121 · Cited by 34 · cited 1×
“PD-1 selectively suppresses aberrant immune responses based on the danger theory ( 24 , 25).”
BackgroundFelix, S. B., & Staudt, A. (2006) · International Journal of Cardiology · doi:10.1016/j.ijcard.2006.05.014 · Cited by 32
Ligands for programmed cell death 1 gene in patients with systemic lupus erythematosus.
Wang, S.-C., Lin, C., Ou, T., Wu, C.-C., Tsai, W., Hu, C., Liu, H.-W., & Yen, J. (2007) · PubMed · Cited by 23
Bennet, A. M., Alarcón-Riquelme, M. E., Wiman, B., Fairé, U. D., & Prokunina‐Olsson, L. (2006) · Human Immunology · doi:10.1016/j.humimm.2006.05.005 · Cited by 17
No evidence of association between genetic variants of the PDCD1 ligands and SLE
Abelson, A.-K., Johansson, C., Kozyrev, S. V., Kristjansdottir, H., Gunnarsson, I., Svenungsson, E., Jönsen, A., Lima, G., Scherbarth, H. R., Gamron, S., et al. (2006) · Genes and Immunity · doi:10.1038/sj.gene.6364360 · Cited by 15
A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese
EKPProkunina-Olsson, LWong, WHSLau, CSChan, TMAlarcom-Riquelme, & MLau (2005) · 中国生物学文摘 · Cited by 14
Lee, S. H., Lee, Y. A., Woo, D. H., Song, R., Kim, Y., Park, E.-K., Ryu, M. H., Kim, K. S., Hong, S. J., Yoo, M. C., et al. (2007) · The Korean Journal of Internal Medicine · Cited by 6
Cited by
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
“All squamous type All doses 13 1 8 (0-36) ND 3 23 (5-54) 43 (15-71)”
InfluentialPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
“A role for PD-1:PD-L in humans is suggested by polymorphisms in PDCD1 that have been associated with human autoimmune diseases, including systemic lupus erythematosus (SLE), type 1 diabetes, rheumatoid arthritis, Grave’s disease, and MS (76).”
BackgroundSafety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
“M1a 1 (2) 3 (19) 6 (25) 3 (9) 1 (5) 14 (10)”
Metadata
- Authors
- Okazaki, T., & Honjo, T.
- Affiliations
- Kyoto University (JP)
- ORCID
- Okazaki, T.
- Venue
- International Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-06-22
- Volume
- 19
- Issue
- 7
- Pages
- 813-824
- ISSN
- 0953-8178 (ISSN-L)
- 1460-2377
- OpenAlex
- W2122639773
- Cited by
- 1,310
- References
- 138
- Citations by year
- 2026: 26 · 2025: 53 · 2024: 96 · 2023: 94 · 2022: 100 · 2021: 125 · 2020: 152 · 2019: 101 · 2018: 100 · 2017: 112 · 2016: 72 · 2015: 70 · 2014: 41 · 2013: 48 · 2012: 29
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Biomedical Innovation
- Japan Society for the Promotion of Science (17047024, 19689012)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-1, PD-L1, PD-L2, immune checkpoint, SHP2, autoimmunity, antitumor immunity, transplantation immunity, allergy, immune privilege, clinical application
- MeSH terms
- Animals, Autoimmune Diseases, Humans, Immunity, Ligands, Antigens, CD, Intercellular Signaling Peptides and Proteins, Mice, B7-H1 Antigen, Programmed Cell Death 1 Ligand 2 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.